SureTrader
Home > Boards > US Listed > Biotechs > Compugen (CGEN)

6:01AM Compugen announces results showing its CGEN-15001T drug

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
surf1944 Member Profile
 
Followed By 427
Posts 23,110
Boards Moderated 3
Alias Born 09/11/06
160x600 placeholder
Compugen Announces Presentations at Three Upcoming Cancer Immunotherapy Conferences "PR Newswire (US)" - 1/2/2018 7:00:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 12/18/2017 6:05:56 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 11/7/2017 7:32:14 AM
Compugen Reports Third Quarter 2017 Results "PR Newswire (US)" - 11/7/2017 7:10:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 11/6/2017 8:01:08 AM
Compugen to Initiate Manufacturing of COM902, its Lead Anti-TIGIT Monoclonal Antibody "PR Newswire (US)" - 11/6/2017 7:00:00 AM
Compugen to Enter Research Collaboration With Mount Sinai on Novel Myeloid Immuno-Oncology Targets "PR Newswire (US)" - 11/2/2017 7:00:00 AM
Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month "PR Newswire (US)" - 10/26/2017 7:00:00 AM
Compugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ET "PR Newswire (US)" - 10/25/2017 7:00:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 10/19/2017 9:41:56 AM
A New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer Therapy "PR Newswire (US)" - 10/9/2017 7:00:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 9/6/2017 7:10:35 AM
Confidential Treatment Order (ct Order) "Edgar (US Regulatory)" - 8/14/2017 3:33:21 PM
Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month "PR Newswire (US)" - 8/7/2017 7:00:00 AM
Compugen Welcomes Paul Sekhri as its New Chairman of the Board "PR Newswire (US)" - 8/2/2017 7:22:00 AM
Compugen Reports Second Quarter 2017 Results "PR Newswire (US)" - 8/2/2017 7:20:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 8/2/2017 7:18:10 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 7/26/2017 7:31:02 AM
Compugen Discloses Updates to Collaborative Activities with Bayer in Immuno-Oncology "PR Newswire (US)" - 7/26/2017 7:09:00 AM
Compugen Announces Issuance of U.S. Patent for COM701, its Lead Immuno-Oncology Product Candidate "PR Newswire (US)" - 7/25/2017 7:00:00 AM
Compugen Second Quarter 2017 Conference Call Scheduled for Wednesday, August 2, 2017 at 10:00 AM ET "PR Newswire (US)" - 7/24/2017 7:00:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 7/14/2017 10:38:05 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 7/13/2017 8:41:33 AM
Compugen Presents at ASCO COM701 Drug Combination Data with TIGIT and PD-1 Inhibitors in Preclinical Models "PR Newswire (US)" - 6/5/2017 9:00:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 5/31/2017 7:01:11 AM
surf1944   Thursday, 02/02/12 10:57:15 AM
Re: surf1944 post# 109
Post # of 160 
6:01AM Compugen announces results showing its CGEN-15001T drug may have potential for cancer immunotherapy (CGEN) 5.30 : Co announced results demonstrating the therapeutic potential of CGEN-15001T as a drug target for treatment of multiple cancers by means of monoclonal antibody ("mAb") therapy. These results indicate that CGEN-15001T is expressed on numerous types of cancer, such as carcinomas, sarcomas, melanoma and hematological cancers as well as on immune cells. These findings, together with previous results supporting its active immunomodulatory effect, 'strongly support CGEN-15001T's potential as a powerful drug target for treatment of various solid and hematological cancers, an area of great interest to the pharmaceutical industry.'


surf's up......crikey



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist